Literature DB >> 14743209

Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas.

Luke Hesson1, Ivan Bièche, Dietmar Krex, Emmanuelle Criniere, Khê Hoang-Xuan, Eamonn R Maher, Farida Latif.   

Abstract

RASSF1A is a major tumor suppressor gene located at 3p21.3. We investigated the role of aberrant promoter region hypermethylation of RASSF1A in a large series of adult gliomas. RASSF1A was frequently methylated in both primary tumors (36/63; 57%) and tumor cell lines (7/7; 100%). Hypermethylation of RASSF1A in glioma cell lines correlated with loss of expression and treatment with a demethylating agent-reactivated RASSF1A gene expression. Furthermore, re-expression of RASSF1A suppressed the growth of glioma cell line H4 in vitro. Next, we investigated whether other members of the RASSF gene family were also inactivated by methylation. NORE1B and RASSF3 were not methylated in gliomas, while NORE1A and RASSF5/AD037 demonstrated methylation in glioma cell lines but not in primary tumors. We then investigated the methylation status of three other candidate 3p21.3 tumor suppressor genes. CACNA2D2 and SEMA3B were not frequently methylated, but the BLU gene located just centromeric to RASSF1 was frequently methylated in glioma cell lines (7/7) and in 80% (35/44) of glioma tumors. In these tumor cell lines, BLU expression was restored after treatment with a demethylating agent. Loss of BLU gene expression in glioma tumors correlated with BLU methylation. There was no association between RASSF1A and BLU methylation. RASSF1A methylation increased with tumor grade, while BLU methylation was seen at similar frequencies in all grades. Our data implicate RASSF1A and BLU promoter methylation in the pathogenesis of adult gliomas, while other RASSF family members and CACNA2D2 and SEMA3B appear to have only minor roles. In addition, RASSF1A and BLU methylation appear to be independent and specific events and not due to region-wide changes in DNA methylation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14743209     DOI: 10.1038/sj.onc.1207407

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

1.  Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.

Authors:  Julien Laffaire; Sibille Everhard; Ahmed Idbaih; Emmanuelle Crinière; Yannick Marie; Aurelien de Reyniès; Renaud Schiappa; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Joëlle Thillet; François Ducray
Journal:  Neuro Oncol       Date:  2010-10-05       Impact factor: 12.300

2.  Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines.

Authors:  Erika da Costa Prando; Luciane Regina Cavalli; Cláudia Aparecida Rainho
Journal:  Epigenetics       Date:  2011-12       Impact factor: 4.528

3.  Loss of heterozygosity and methylation of multiple tumor suppressor genes on chromosome 3 in hepatocellular carcinoma.

Authors:  Xiaoying Zhang; Hiu Ming Li; Zhiyan Liu; Gengyin Zhou; Qinghui Zhang; Tingguo Zhang; Jianping Zhang; Cuijuan Zhang
Journal:  J Gastroenterol       Date:  2012-07-06       Impact factor: 7.527

Review 4.  Epigenetic principles and mechanisms underlying nervous system functions in health and disease.

Authors:  Mark F Mehler
Journal:  Prog Neurobiol       Date:  2008-10-17       Impact factor: 11.685

Review 5.  Integration and analysis of genome-scale data from gliomas.

Authors:  Gregory Riddick; Howard A Fine
Journal:  Nat Rev Neurol       Date:  2011-07-05       Impact factor: 42.937

6.  Genetic and pathologic evolution of early secondary gliosarcoma.

Authors:  Kari-Elise T Codispoti; Stacy Mosier; Robert Ramsey; Ming-Tseh Lin; Fausto J Rodriguez
Journal:  Brain Tumor Pathol       Date:  2013-01-17       Impact factor: 3.298

Review 7.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12

8.  Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1.

Authors:  Yue Guo; Limin Shu; Chengyue Zhang; Zheng-Yuan Su; Ah-Ng Tony Kong
Journal:  Biochem Pharmacol       Date:  2015-01-29       Impact factor: 5.858

Review 9.  The ubiquitin proteasome system in neuropathology.

Authors:  Norman L Lehman
Journal:  Acta Neuropathol       Date:  2009-07-14       Impact factor: 17.088

10.  The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.

Authors:  Luke B Hesson; Thomas L Dunwell; Wendy N Cooper; Daniel Catchpoole; Anna T Brini; Raffaella Chiaramonte; Mike Griffiths; Andrew D Chalmers; Eamonn R Maher; Farida Latif
Journal:  Mol Cancer       Date:  2009-07-01       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.